FDA Mirvetuximab soravtansine-gynx coverage for business development, investment, and market access teams
The FDA has granted accelerated approval for Mirvetuximab Soravtansine, branded as Elahere, offering new hope for patients with ovarian cancer.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
